UnitedHealth is finally getting its act together. I'm buying into the turnaround

UnitedHealth’s Q3 medical care ratio fell to 88.4% from 89.9% a year earlier, adjusted EPS of $4.69 beat expectations, and the company raised full-year adjusted EPS guidance to at least $20.50. Optum generated $66.9 billion in revenue and $3.7 billion in operating earnings; UnitedHealth plans nearly $1.5 billion in technology investment in 2026, including AI. The contributor sees a turnaround under returning CEO Stephen Hemsley, while noting medical-cost trends remain a risk; shares are up about 27% year to date and 11% below their 52-week high.

Analysis

The improvement is more useful as evidence that the earnings reset may be stabilizing than as proof the old growth model is restored. The key test is whether medical-cost discipline persists across enrollment and utilization cycles: a favorable medical care ratio can reverse quickly if care use rises or Medicare Advantage reimbursement and risk-adjustment economics disappoint. Track the ratio alongside membership mix and guidance, not in isolation.

Optum diversifies revenue streams, but it does not fully diversify the risk: payer, provider, and pharmacy operations remain exposed to the same reimbursement, utilization, and regulatory environment. Vertical integration may support coordination and scale, while also inviting scrutiny of how affiliated businesses affect patients, providers, and competitors such as CVS, Elevance Health, and Cigna. AI is a potential margin lever, not yet a demonstrated earnings driver; automation savings could be delayed by implementation costs or constrained by clinical and regulatory requirements.

Near term, the turnaround narrative and CEO’s personal purchase may already support sentiment, so another earnings beat alone may have less upside impact than a renewed cost miss has downside. Over 1–3 months, watch medical-cost trends, enrollment mix, and management’s ability to sustain guidance. Over 6–18 months, CMS payment decisions, regulatory actions affecting Medicare Advantage or pharmacy-benefit practices, and evidence of realized technology productivity are the larger catalysts. The bullish case is falsified by a renewed deterioration in medical costs, a guidance cut, or material adverse reimbursement changes. The article’s historical leadership comparison and stated growth ambition are not substitutes for independently verified delivery.

Key Decisions for Investors

• Treat UNH as a conditional turnaround exposure, not a confirmed return to its prior growth trajectory. Consider initiating or adding only if subsequent reporting sustains the medical-cost improvement and guidance.
• For existing exposure, retain a defined review trigger: reassess on a medical care ratio reversal, a cut to earnings guidance, or adverse CMS/reimbursement developments. Avoid relying on the ratio alone; check enrollment and business mix.
• Do not pay for the AI thesis ahead of evidence. Track whether technology investment translates into measurable operating productivity and lower administrative costs over the next 6–18 months.
• The contrarian risk is asymmetric narrative fatigue: optimism about the CEO and recovery may be priced more readily than uncertainty around utilization and policy. If UNH rallies on guidance without improved underlying cost indicators, avoid chasing; a broad health-insurer position is preferable to a concentrated AI-driven thesis.